Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy

This study has been terminated.
(This study was stopped because of an inadequate rate of enrollment.)
Sponsor:
Information provided by:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
ClinicalTrials.gov Identifier:
NCT00083434
First received: May 24, 2004
Last updated: April 25, 2011
Last verified: April 2011

May 24, 2004
April 25, 2011
February 2004
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00083434 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy
Not Provided

The purpose of this study is to examine the effectiveness of epoetin alfa in treating anemia in patients who have cancer or who no longer have any signs of the cancer, but remain anemic as a result of their treatment.

Not Provided
Interventional
Phase 3
Endpoint Classification: Efficacy Study
Primary Purpose: Treatment
  • Anemia
  • Cancer
Drug: Epoetin alfa
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
Not Provided
October 2004
Not Provided

Inclusion Criteria:

  • 18 years of age or older
  • Body weight >/= 99lbs
  • ECOG 0-2
  • Anemia results from cancer, chemotherapy, radiotherapy or an association with hormonal therapy or immunotherapy
  • Screening hemoglobin level of </= 11.0 g/dL for men or </= 10.0 for women

Exclusion Criteria:

  • History of or concurrent second malignancy
  • Evidence of primary or metastatic malignancy involving the Central Nervous System
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00083434
CR010549, EPO-CAN-303
Yes
Not Provided
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Not Provided
Not Provided
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
April 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP